A recent OIG report examined drug costs to Medicaid pharmacies and their relation to benchmark prices to inform states as they consider changes to their drug reimbursement methodologies. The OIG concluded that average wholesale price, wholesale acquisition cost, and AMP had consistent relationships with invoice prices for single-source drugs. None of these benchmarks had consistent relationships with invoice prices for multiple-source drugs without FULs, the OIG observed (with AMP being the least consistent benchmark). The OIG suggests that states might better approximate drug invoice prices by developing different reimbursement methodologies for single-source drugs, brand-name multiple-source drugs, and generic multiple-source drugs.